Stock Scorecard

Stock Summary for Alterity Therapeutics Ltd (ATHE) - $4.40 as of 6/13/2025 5:57:39 PM EST

Total Score

10 out of 30

Safety Score

11 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ATHE

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ATHE

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ATHE

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ATHE

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ATHE (11 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 0
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 1
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ATHE

Alterity Therapeutics Prominently Featured at the International MSA Congress - Alterity Therapeutics ( NASDAQ:ATHE ) 5/12/2025 11:35:00 AM
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress - Alterity Therapeutics ( NASDAQ:ATHE ) 5/7/2025 12:16:00 PM
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy 5/5/2025 11:35:00 AM
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy - Alterity Therapeutics ( NASDAQ:ATHE ) 5/5/2025 11:35:00 AM
Appendix 4C - Q3 FY25 Quarterly Cash Flow Report 4/30/2025 11:35:00 AM
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium - Alterity Therapeutics ( NASDAQ:ATHE ) 4/28/2025 11:35:00 AM
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting - Alterity Therapeutics ( NASDAQ:ATHE ) 4/3/2025 11:35:00 AM
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting 4/3/2025 11:35:00 AM
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy 3/27/2025 11:25:00 AM
Alterity Therapeutics Raises A$40.0 million in Placement 2/10/2025 12:25:00 PM

Financial Details for ATHE

Company Overview
Ticker ATHE
Company Name Alterity Therapeutics Ltd
Country USA
Description Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinson's disease and other neurodegenerative diseases in Australia. The company is headquartered in Melbourne, Australia.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2024
Next Earnings Date 8/4/2025

Stock Price History
Last Day Price 4.40
Price 4 Years Ago 7.20
Last Day Price Updated 6/13/2025 5:57:39 PM EST
Last Day Volume 22,706
Average Daily Volume 66,032
52-Week High 5.87
52-Week Low 1.00
Last Price to 52 Week Low 340.00%

Valuation Measures
Trailing PE N/A
Industry PE 22.59
Sector PE 40.97
5-Year Average PE -464.30
Free Cash Flow Ratio 14.19
Industry Free Cash Flow Ratio 17.94
Sector Free Cash Flow Ratio 31.90
Current Ratio Most Recent Quarter 3.84
Total Cash Per Share 0.31
Book Value Per Share Most Recent Quarter 0.00
Price to Book Ratio 14.18
Industry Price to Book Ratio 34.46
Sector Price to Book Ratio 30.10
Price to Sales Ratio Twelve Trailing Months 18.68
Industry Price to Sales Ratio Twelve Trailing Months 120.34
Sector Price to Sales Ratio Twelve Trailing Months 34.15
Analyst Buy Ratings N/A
Analyst Strong Buy Ratings N/A

Share Statistics
Total Shares Outstanding 14,803,400
Market Capitalization 65,134,960
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.61%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -38.51%
Reported EPS 12 Trailing Months -2.07
Reported EPS Past Year 0.00
Reported EPS Prior Year -0.24
Net Income Twelve Trailing Months -26,097,757
Net Income Past Year -19,123,464
Net Income Prior Year -13,806,515
Quarterly Revenue Growth YOY -15.50%
5-Year Revenue Growth 105.93%
Operating Margin Twelve Trailing Months -469.70%

Balance Sheet
Total Cash Most Recent Quarter 4,536,559
Total Cash Past Year 12,638,885
Total Cash Prior Year 15,773,783
Net Cash Position Most Recent Quarter 4,536,559
Net Cash Position Past Year 12,638,885
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 13,798,057
Total Stockholder Equity Prior Year 22,812,909
Total Stockholder Equity Most Recent Quarter 7,786,007

Free Cash Flow
Free Cash Flow Twelve Trailing Months -16,470,784
Free Cash Flow Per Share Twelve Trailing Months -1.11
Free Cash Flow Past Year -12,611,546
Free Cash Flow Prior Year -20,043,148

Options
Put/Call Ratio 0.00
Has Options False
Liquidity Rating None

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.20
MACD Signal 0.22
20-Day Bollinger Lower Band 2.89
20-Day Bollinger Middle Band 3.97
20-Day Bollinger Upper Band 5.04
Beta 0.72
RSI 56.74
50-Day SMA 2.90
150-Day SMA 0.00
200-Day SMA 4.45

System
Modified 6/13/2025 5:58:26 PM EST